first domest mover massiv market
massiv china biolog market china biolog market still
earli stage develop penetr rate low due previou
slow approv process high drug price market enjoy strong
growth driven acceler approv better insur coverag
biolog grow compound-annual-growth-rate reach bn believ
domest compani biggest winner price cost advantag
first approv domest toripalimab china largest patient
base top respons tumour expect market size
bn junshi approv treat melanoma
patient first approv prc compani estim
toripalimab gener mn sale
sale mainli contribut off-label sale
humira biosimilar one first biosimilar receiv ind
china nmpa recruit phase clinic trial junshi
aim file nda nmpa launch
defens polici headwind recent polici gener
pressur gpo group purchas organis chronic diseas
drug face price cut innov biolog rel
less competit
manufactur biolog much higher barrier biolog compani
limit incent lower drug price gain market share
polici
market
initi outperform rate tp upsid like
compani lead posit china biolog strong intern
capac mainli use multipl stage dcf deriv tp
market cap bn use wacc perpetu growth rate
closest compar compani innov valu
bn major invest risk view includ
failur drug approv risk delay approv manufactur
risk drug price cut price war risk oper cash flow
valuat metric
chg prev ep
number share mn
price month
price rel chart measur perform
china close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
charl martineau pm univers toronto focu chart tabl
figur china patient
figur three scenario compani revenu
figur sale forecast toripalimab us mn
indic combo
market valu pre-
charl martineau pm univers toronto demand new
therapi quit
strong china
china largest
patient base
nda
first domest mover massiv market
compani first domest mover china biolog market first prc
compani approv first-mov advantag enorm
healthcar landscap data drug show first three mover could
retain around market share ten year launch
strong demand domest biolog
demand new therapi quit strong china support well-establish
regulatori landscap increas dispos incom better insur coverag
china biolog market still earli stage believ upsid potenti
enorm demand cutting-edg therapi quit strong mn opdivo
bm keytruda merck total deliv end opdivo
commercialis august keytruda septemb frost
sullivan expect biolog market grow bn sale
compound-annual-growth-rate china chines compani well posit market price
advantag much improv capac
first domest mover china market
consid respons incid rate china largest patient base top-
respons tumour around mn incid compar mn us
mn countri junshi first domest mover china
market first prc compani file ind investig new drug applic
nda new drug applic receiv drug approv nmpa nation medic
product administr toripalimab shown higher respons rate melanoma
compar keytruda merck believ sale surg post market
launch doctor major hospit alreadi well educ prescrib pd-
follow first approv indic second-lin treatment melanoma
expect indic would expand first-lin melanoma nasopharyng
carcinoma one cancer highest incid rate china
per cancer statist china
junshi rich pipelin biolog biosimilar inhibitor
humira biosimilar mab bli
mab clinic trial stage humira biosimilar one first humira
biosimilar receiv ind china nmpa recruit phase clinic
trial junshi target file nda nmpa launch
drug main sourc revenu next
year
initi outperform tp
deriv tp base multi-stag dcf assum wacc
perpetu growth rate base base case scenario stock trade around
discount biotech compani trade market cap rang
bn major invest risk view includ risk drug approv
clinic test expens take mani year complet outcom
inher uncertain risk delay drug approv risk biolog manufactur
drug price cut oper risk junshi gener revenu
signific cost expect futur risk current experienc
manag may depart team risk reput damag face
shanghai junshi bioscienc innovation-driven bio-
pharmaceut focus innov drug first prc
compani file ind nda applic receiv approv
nmpa mab also product
bli pipelin
good sold
profit tax
free cash flow firm
net chang cash
blue sky target price base strong off-label
sale first three year approv ndrl inclus
less price cut faster-than-expect
approv
grey sky target price base major
indic competitor approv faster expect
ndrl inclus within five year weaker-than-
price rel chart measur perform china
close
spot exchang rate
charl martineau pm univers toronto tabl content
first domest mover massiv market
focu chart tabl
first domest mover massiv market
strong demand domest biolog
first domest mover china market
initi outperform tp
strong demand domest biolog
chanc domest compani
first domest mover china market
first prc compani get nda
enorm first-to-market advantag pharmaceut
collabor bring opportun
huge market potenti
domest leader anti-tnf drug develop rheumatoid
domest front mover next-gener hypercholesterolemia therapi
domest player anti-bl field
initi outperform tp
valuat deriv compar compani
board
charl martineau pm univers toronto opdivo keytruda
sale
sale compound-annual-growth-rate
global biolog
strong demand domest biolog
demand new cutting-edg therapi quit strong china
acceler approv process cutting-edg therapi start usual took
mnc anoth five year get drug approv china global approv
develop china biolog market much delay due approv
process high price situat chang support acceler
approv process increas dispos incom grow capit invest
exampl shanghai pharma deliv mn opdivo keytruda total
end opdivo commercialis august keytruda around
septemb two drug includ public insur thu
paid pocket patient without insur
believ compani like junshi stand strong intern capac
manag team eleven thirteen pipelin product develop
compani drug discoveri stage besid junshi differenti
biotech compani strong diversifi sale team chairman xiong jun
rich experi chairman sever compani includ pharma compani dr li
ning ceo use vice presid asia regulatori affair sanofi strong
experi drug registr dr feng hui rich experi drug
manag team aggreg hold higher averag
global biolog enjoy sale compound-annual-growth-rate superior efficaci
increas invest develop technolog per frost sullivan data
global biolog market grow compound-annual-growth-rate next four year reach
mn part sale driven biosimilar due sever origin drug
patent due expir
monoclon antibodi mab bind ligand receptor cell surfac therebi
target signal pathway
prevent downstream effect mab account biolog revenu accord
frost sullivan
figur global biolog deliv compound-annual-growth-rate
grow compound-annual-growth-rate
next four year
china biolog market still earli stage believ upsid potenti
enorm expect grow bn sale compound-annual-growth-rate per
invest support govern polici better insur coverag increas
afford major driver meanwhil biosimilar market growth outpac
biolog market growth product avail price advantag
mnc use price drug similar price prc compar us
regardless afford humira deliv mn sale kit
flat compar patient strong critic clinic need drug
approv china bought drug oversea purchas
even though chines regul work acceler new drug approv
still lot cutting-edg drug therapi approv china patient suffer
critic diseas especi cancer cardiovascular problem start
seek better treatment regul market us japan current two
popular destin base data sant lucia consult one
earliest cross-bord medic consult agenc averag asp averag spend
per patient treatment
figur top destin cross-bord medic
chines regul acceler approv drug strong clinic need
give prioriti review also initi nation drug negoti process play
wholesal buyer negoti mnc domest compani cut drug
price includ ndrl nation drug reimburs list regul
reform pharmaceut mainli focus drug qualiti new drug approv
figur focu pharmaceut polici
requir bioequival test
grant short-cut mnc
drug approv china
remov hospit
regulatori landscap readi includ acceler drug approv improv
patient afford believ growth china biolog market surg
next year china biolog expect grow compound-annual-growth-rate reach
bn per frost sullivan
figur china biolog market deliv compound-annual-growth-rate
chanc domest compani
believ strong demand patient reform regulatori system benefit
domest compani central local govern provid larg subsidi
healthcar includ govern grant free land use right govern fund
invest exampl guangzhou govern cooper beigen
construct manufactur site biolog invest mn project
patent quit blockbust biolog expir believ chines
compani effect compet mnc china biosimilar market given
price advantag
charl martineau pm univers toronto compani file first
strong growth
first domest mover china market
china biotech sector enjoy strong growth sinc driven increas capit
invest grow number returne support govern polici
capit invest china pharmaceut industri reach bn
account global invest quit unicorn grew period
junshi one first tier prc biotech compani focus develop
program death program death-ligand
emerg import target biomark immunotherapi proven
improv safeti efficaci treat sever cancer junshi first
domest mover china market first prc compani file ind applic
nda nmpa well first pcr compani receiv drug approv
fda approv keytruda treat solid tumour specif genet
featur make keytruda first therapi approv base specif genet featur
regardless cancer type
global market continu grow intens competit
global sale surg first therapi keytruda
approv septemb opdivo bm three month
keytruda opdivo total record bn sale
second/third full year launch tecentriq roch deliv
mn sale launch octob sale ramp
mn imfinzi az approv fifth
therapi keytruda approv first drug solid tumour
figur product approv world-wide
base data research agenc research market
drug approxim activ clinic trial trial new drug
combin therapi global market increas compound-annual-growth-rate
bn bn expect increas
bn estim
china one
expect china one largest market long run
largest respons patient consid respons incid rate
china largest patient base respons tumour around mn
incid per year compar mn us mn countri
respons rate differ cancer vari base
studi cancer publish new england journal medicin indic
cutan squamous-cel merkel-cel melanoma non-colorect mmrd cancer
respons tumour respons rate asian patient slightli differ
studi
among cancer type nsclc gastric cancer oesophag
largest sale potenti china larg respons patient base
expect largest driver market china
charl martineau pm univers toronto figur correl tumour mutat burden object respons rate
therapi tumour type
new england journal medicin
new england journal medicin
charl martineau pm univers toronto figur incid respons tumour
figur china address market major
china data us data data japan data
opdivo keytruda approv china alreadi june juli
respect opdivo deliv mn product pharmaci first day
commercialis junshi becam first chines compani get
approv drug nine-month review process prc
market estim grow bn increas bn
meanwhil market share prc compani continu increas reach
sale base follow
assumpt million new cancer incid newli diagnos patient
suitabl treatment drug penetr reach
suitabl patient two-year averag treatment durat
decemb
first prc compani get nda approv
current four approv product china two opdivo keytruda
mnc two toripalimab sintilimab domest biotech compani
addit two domest compani beigen hengrui file nda
nmpa clinic trial carri china
recruit patient doctor larg hospit well
educ new therapi help boost drug sale launch
charl martineau pm univers toronto figur approv hand nda china
unresect local progress metastat
relaps refractori classic hodgkin
market quit competit believ first two mnc first four
domest compani market among first tier pd-
compani keytruda toripalimab indic cover melanoma
long term believ major cancer china nsclc urotheli
carcinoma gastric cancer player mnc drug alreadi
approv indic largest market potenti china
figur china applic clinic trial comparison
oesophag cancer ec enktl recurr refractori hodgkin lymphoma
nsclc advanc oesophag cancer advanc liver cancer combo apatinib
nsclc advanc liver cancer advanc nsclc recurr refractori hodgkin lymphoma enktl
recurr metastat nasopharyng carcinoma advanc solid tumour
enorm first-to-market advantag pharmaceut
studi analys drug launch show first-to-market
player averag could keep larger market share ten year launch
charl martineau pm univers toronto figur first entrant averag achiev higher market share ten year
market
market
market
market
market
market beyond
junshi carri
clinic trial
toripalimab variou
toripalimab junshi antibodi compani carri
clinic trial toripalimab variou cancer includ malign melanoma urotheli
cancer breast cancer neuroendocrin tumour lymphoma sarcoma toripalimab
got nmpa approv second line treatment unresect local progress
metastat melanoma target launch time toripalimab china
compani also receiv ind approv fda current undergo phase
clinic trial unit state
figur clinic trial statu toripalimab
pre-clin featur high affin strong internalis induct
featur toripalimab mainli includ high affin strong internalis
induct bind affin typic measur report equilibrium
dissoci constant kd use evalu rank order strength
biomolecular interact smaller kd valu greater bind affin
ligand target
figur kd launch product toripalimab
cell imag result show signific decreas express cell surfac
demonstr internalis induc toripalimab simultan stain
toripalimab non-competit mab
figur reduct membran surfac induc toripalimab
clinic trial registr statu key result
toripalimab preliminary/ phase i/ phase ii result demonstr great efficaci base
orr overal respons rate dcr diseas control rate although cross trial
comparison inform toripalimab shown better orr rate china
melanoma keytruda preliminari result indic in-lin two
mnc three domest competitor consid clinic trial scale data
think toripalimab potenti first tier drug chines market one
downsid risk toripalimab market potenti rel earli clinic develop
stage big indic nsclc
figur orr dcr toripalimab clinic studi
indic phase trial
advanc refractori alveolar soft part sarcoma
advanc metastat urotheli carcinoma ii
refractori metastat nasopharyng carcinoma ii
figur summari clinic trial result toripalimab five compet product
approv nmpa review
advanc metastat urotheli
phase ii clinic trial advanc melanoma design treat patient
fail system treatment trial recruit advanc melanoma patient total
patient least six month follow-up orr rate dcr
weight averag differ advanc melanoma orr percent highest csd
chronic sun damag non-csd melanoma patient patient belong csd
non-csd account china melanoma patient
figur efficaci result clinic trial toripalimab treatment advanc melanoma
note asco
note asco
charl martineau pm univers toronto figur optim tumour shrinkag rate advanc melanoma patient
treat toripalimab
besid data show efficaci posit melanoma patient better
neg patient orr respect base clinic
result toripalimab receiv nmpa approv second line treatment melanoma
keytruda also approv china patient advanc melanoma juli
compar clinic trial data focu respons rate advers effect rate
chines patient keytruda lower respons rate less ratio compar
toripalimab keytruda progression-free-surviv rate
month surviv rate data surviv rate
disclos toripalimab yet orr keytruda melanoma patient much lower
china patient patient regist us trial versu
toripalimab orr china melanoma patient slightli higher keytruda
biggest differ two drug orr csd non-csd
patient toripalimab achiev orr keytruda orr
although cross clinic trial result comparison inform still serv
market point commercialis superior efficaci could confirm
post market real world treatment boost toripalimab market penetr
charl martineau pm univers toronto figur orr keytruda toripalimab
keytruda csd/non-csd melanoma
toripalimab csd/non-csd melanoma
anoth import strategi increas market penetr price advantag accord
manag price toripalimab translat
averag monthli cost per patient dose per two week
consid pap patient assist plan annual cost toripalimab around
per patient discount merck keytruda price china
think aggress price strategi could help toripalimab win larger market share
melanoma off-label indic near term long run drug
includ nrdl better proven clinic benefit play bigger role physician
refractori metastat nasopharyng carcinoma phase ii
phase ii clinic trial refractori metastat nasopharyng carcinoma recruit
patient patient underw least one efficaci evalu orr
dcr also show efficaci posit tumour patient
better neg patient orr dcr posit tumour patient
respect
charl martineau pm univers toronto figur optim tumour shrinkag rate advanc nasopharyng cancer
patient treat toripalimab
phase ib/ii trial advanc esophag squamou cell carcinoma among
patient evalu orr dcr
figur optim tumour shrinkag rate advanc esophag cancer
patient treat toripalimab phase ib/ii clinic trial
phase ib/ii trial advanc gastric adenocarcinoma among patient
evalu orr dcr
charl martineau pm univers toronto figur optim tumour shrinkag rate advanc gastric adenocarcinoma
patient treat toripalimab phase ib/ii clinic trial
collabor bring opportun
besid monotherapi compani work also cooper
compani work combin therapi toripalimab cooper
cspc develop combin therapi toripalimab paclitaxel
breast cancer also work betta pharma treat mucos
melanoma believ collabor partner combo would help junshi
save expens expand indic allow leverag partner sell
market resourc
figur three combin deal toripalimab
cspc charg clinic trial
combin appli approv
market sell product china junshi
receiv mileston payment
mn five mileston event
aggreg mn
junshi rich pipelin biolog biosimilar inhibitor
compani product humira biosimilar mab
bli mab clinic trial stage humira biosimilar first humira
biosimilar receiv ind china nmpa recruit phase clinic
trial finish compani target file nda nmpa
launch drug junshi expect sale toripalimab
main sourc revenu next year
figur key pipelin product clinic trial
ramp
huge market potenti biosimilar
biosimilar follow-on version innov biopharmaceut separ
develop patent protect expir similar qualiti safeti
efficaci innov biopharmaceut
global pcr biosimilar market enjoy rapid expans recent
year driven factor larg number blockbust biolog near-term
mid-term expir cost advantag biosimilar improv regulatori pathway
compound-annual-growth-rate global biosimilar market estim compound-annual-growth-rate
pcr biosimilar market remain rel small growth rate
project increas significantli compound-annual-growth-rate
main drive forc rapid expans china biosimilar market
patent expir larg number blockbust biolog
patent six top best-sel biolog expir
near futur give substanti market opportun biosimilar similar
qualiti afford price
charl martineau pm univers toronto figur revenu patent expiri time blockbust biolog
mileston china biosimilar market recent year releas
guidelin evalu biosimilar nmpa set
clear registr pathway biosimialr china guidelin
biosimilar need perform seri head-to-head comparison refer
drug pre-clin clinic studi demonstr high similar
approv significantli strengthen qualiti biosimilar
time increas entri barrier biosimilar industri think high approv
standard foster trust physician patient biosimilar
eventu boost market share
huge room new comer
biosimilar industri still new territori china huge upsid potenti
new comer biosimilar approv biosimilar
guidelin china yet hand absolut size biosimilar
market share china biolog market small compar global
market china biosimilar market bn account
biolog market comparison global biosimilar market
reach bn repres biolog market
biosimialr launch chines market expect market share
increas significantli match global level
domest leader anti-tnf drug develop
tnf- potent induc inflammatori respons anti-tnf- monoclon
antibodi suppress tnf- immun respons new gener therapi
treat immun mediat inflammatori diseas high efficaci safeti profil
humira first fulli human antibodi tnf- approv fda treatment
rheumatoid arthriti ra sinc indic extend
autoimmun diseas psoriat arthriti idiopath arthriti jia
ps among other due larg patient pool well desir efficaci
excel safeti humira becom best-sel drug sinc
revenu reach bn expect reach sale peak revenu
bn humira biosimilar estim reach bn
compound-annual-growth-rate
humira approv nmpa treatment rheumatoid arthriti ra
ankylos spondyl psoriasi ps prc humira revenu prc
rel small due low penetr rate expans drug launch
cost-friendli humira biosimilar prc market market size estim
grow bn compound-annual-growth-rate
reach bn
charl martineau pm univers toronto figur histor forecast global
figur histor forecast china
product develop statu data summari
biosimilar humira adalimumab recombin human anti-tnf-
monoclon antibodi treatment autoimmun diseas approv
nmpa conduct clinic trial may one first clinic stage humira
biosimilar develop prc compani preclin structur function
pharmacokinet studi demonstr highli similar humira
peptid fingerprint compar humira liquid chromatography-
mass spectroscopy/mass spectroscopi lc-ms/m experi indic two
protein amino acid primari structur pharmacokinet studi
show subcutan inject humira rat dose
rel bioavail humira period day
indic compar pharmacokinet behaviour compar pk result also
observ cynomolgu monkey
figur similar lc-ms/m result humira
pharmacokinet comparison studi rat
comparison studi cynomolgu monkey
term efficaci pre-clin studi show mg/kg treatment
group incid rate spontan arthriti htnf transgen rata decreas
incid score histochem score significantli lower
figur impact ra morbid sever human tnf- transgen mice
base pre-clin result approv nmpa conduct
clinic trial may sinc compani conduct concurr
phase clinic trial moder sever ra patient randomis double-
blind phase clinic trial subject demonstr similar safeti profil
humira phase clinic trial enrol patient
complet compani plan file nda nmpa second half
februari compani enter collabor research develop
commercialis agreement t-mab accord agreement develop
cost futur profit equal share compani t-mab respons
manufactur sale
five fda-approv tnf- origin biolog market unit state
five humira biosimilar phase clinic trial us pcr two
market anti-tnf- biolog includ humira multi-national compani
addit nine anti-tnf- biolog clinic trial prc includ five
phase product among late stage product ra indic
one preval autoimmun diseas affect chines popul
figur anti-tnf- monoclon antibodi prc
next-gener
hypercholesterolemia major risk factor cardiovascular diseas treatment
shown cardiovascular benefit hypercholesterolemia incid china
increas recent year mn mn expect
increas mn due unhealthi lifestyl age popul
accord report
statin first-lin therapi hypercholesterolemia patient statin
intoler efficaci sever patient limit repres huge unmet
need proven promis treatment target lower serum cholesterol whose
function bind prevent receptor -r recycl inhibitor block
interact -r thu enhanc cholesterol -c
clearanc plasma clinic data indic inhibitor also reduc
incid heart attack stroke coronari revascularis adult
establish cardiovascular diseas due excel clinic outcom distinct
compani front
domest mover
next-gener
mechan statin drug potenti becom next blockbust
drug cardiovascular diseas current two market antibodi
alirocumab sanofi/regeneron evolocumab alirocumab
evolocumab gener revenu mn mn respect
market project grow rapidli futur bn bn
respect
figur histor forecast global
product develop statu data summari
monoclon antibodi new structur
identifi type high affin facilit pre-clin efficaci evalu
pre-clin data demonstr good efficaci safeti pk/pd profil
repeat inject hyperlipidemia macaca mulatta result reduct
ldl-c obviou side effect observ single-dos repeated-dos toxic
studi macaca fasciculari rattu norvegicu
figur effect inject ldl-c level hyperlipidemia macaca
base data august becam first antibodi
develop prc compani receiv ind approv prc compani
current carri phase clinic trial
august amgen evolocumab receiv approv nmpa first
inhibitor treatment homozyg famili hypercholesterolemia prc
addit five antibodi clinic trial stage prc
figur inhibit drug prc
compani
domest player anti-
domest player anti-bl field
system lupu erythematosu sle autoimmun diseas bodi
immun system mistakenli attack healthi tissu mani part bodi affect
mn peopl world-wide sle popul prc grew steadili
number reach frost sullivan estim rise
treatment option sle limit immunosuppress
hormonotherapi bli immunostimul necessari maintain normal immun
play central role b-cell surviv function excess level bli caus
abnorm high antibodi product result system lupu erythematosu rheumatoid
arthriti mani autoimmun diseas therefor inhibit biolog activ
bli potenti help treatment diseas fda approv
anti-bl antibodi belimumab sle treatment remain target
therapi sle market whose global revenu reach bn
figur histor forecast global bli
product develop statu data summari
first anti-bl monoclon antibodi develop prc
compani obtain ind approv nmpa licensed-in wuhan huaxin
kangyuan biopharma co ltd whkb tent mileston payment
mn net profit
pre-clin studi demonstr promis featur high affin
slow dissoci rate high safeti profil typic pharmacokinet behaviour base
result compani receiv ind approv nmpa octob
advanc clinic trial
gsk belimumab junshi two bli antibodi
obtain ind approv nmpa besid bli sever compani develop
sle therapi target btk
figur clinic stage bli antibodi prc
initi outperform tp
use two method drive valuat rang junshi dcf peer comparison
drive ten-year sale model ad sale forecast drug candid
late-stag clinic trial also done sensit test sale chang
drug penetr rate market share within specif drug categori success rate
dcf use multi-stag dcf model drive compani valuat bn
target price assum wacc perpetu growth rate base three
scenario cost debt assumpt similar junshi last borrow rate
bank use beta
peer comparison also justifi estim junshi valuat rang
bn base market valuat compar compani similar pipelin
composit develop stage
build revenu model ad potenti key product sale indic
enter clinic trial stage drive drug sale indic base
patient base respons rate specif target diagnos ratio drug penetr rate
junshi market share asp drug approv success rate
figur base case revenu model junshi us mn
basic use three factor drive base blue sky grey sky scenario
lower drug penetr rate market share success rate grey sky scenario
factor system risk competit capac hand improv
factor blue sky scenario
figur assumpt three scenario
gross margin believ compani gross margin peak stabilis
around long term volum smaller first three year approv
lead lower gross margin later assum gross margin declin slightli everi
year enter matur stage drug life cycl face price cut pressur polici
 expens expect expens
due clinic trial enter late stage clinic trial long term forecast
 expens stay around total drug sale rank top
among china pharma compani biotech firm estim compani
around bn net cash end enough around three
year oper largest expens account around oper expens
next three year
sell market expens sell market expens per revenu
higher first three year due small sale volum stabilis total
sale view ratio lower current industri averag believ
long term less resourc spent sell market driven recent
polici enter hospit form standard long term believ
allow compani spend fewer resourc market
use multi-stag dcf model deriv compani valuat bn
target price assum wacc perpetu growth rate base
three scenario cost debt assumpt similar compani last
borrow rate bank also use similar wacc junshi beigen junshi
alreadi list neeq nation equiti exchang quotat use
lower wacc compar biotech compani compani key product pd-
alreadi approv
charl martineau pm univers toronto figur discount rate junshi dcf model
debt
pre-tax debt
after-tax debt
equiti
risk-fre rate return
equiti
weight averag capit
capital-expenditure rate chang revenu
less chang work capit
npv cash-flow
npv perpetu
share basic
valuat deriv compar compani
estim junshi valuat rang bn base valuat
compar compani similar pipelin composit similar develop
stage main factor includ number pipelin product whether
clinic stage product compani right sale china
beigen go share net profit celgen innov go
share key product includ
charl martineau pm univers toronto figur comp tabl china biotech compani
note februari
among compar compani found junshi similar innov
thu perform head-to-head comparison compani season
manag team integr platform similar pipelin strategi develop
stage nevertheless opinion junshi differenti featur
manag team still hold around compani share repres better
control power incent compani oper junshi intern capabl
enabl less depend partner drug gain better economi
commercialis stage fewer biosimilar product reflect
figur head-to-head comparison junshi innov
season execut complementari
expertis clinic trial registr
commercialis oper
aggreg hold share
manag team around
integr technolog system cover
entir process biolog earli
stage industrialis
strong intern capabl antibodi
engin screen innov drug
cspc develop combin therapi
toripalimab albumin bound paclitaxel
betta pharma develop toripalimab
vorolanib combin therapi mucos
hcm develop combin therapi
toripalimab sulfatinib
senior manag team proven track record
success
aggreg hold share manag
team around
integr platform entir biolog valu
control clinic trial commercialis
lilli co-develop co-commercialis
adimab discoveri optimis antibodi
direct
hanmi develop commercialis
protevo develop
junshi biopharma innovation-driven biopharmaceut compani dedic
discoveri develop innov biolog well biosimilar drug
compani establish integr technolog system cover entir
process protein drug earli stage industrialis foster
compet set three centr world-wide among san francisco
lab maryland lab primarili focu mechan studi known novel
target drug discoveri screen suzhou centr mainli conduct
function verif process develop drug candid
leverag advanc platform global integr process
compani develop collect drug candid compromis biolog
includ first ind nda file domest monoclon nmpa
antibodi first prc compani receiv ind approv nmpa
monoclon antibodi anti-bl monoclon antibodi
junshi biopharma establish decemb limit liabil compani
own equal mr zhang zhuob mr jikuan mr transfer
share longer sharehold januari mr xiong jun mr
xiong fengxiang becam sharehold hold aggreg equiti interest
compani immedi follow acquisit share may compani
convert joint-stock limit liabil compani renam shanghai junshi
bioscienc co ltd compani share becam list neeq august
june complet merger shanghai union biopharm
compani two monoclon antibodi product base wujiang lingang
wujiang product base establish drug product licenc
respons pilot commerci product compani perform
technolog upgrad wujiang product base rais capac current
end construct lingang product base
start first two product line includ
ferment capabl satisfi need large-scal commerci manufactur
futur
figur mileston compani develop
establish limit liabil compani prc name
mr xiong jun mr xiong fengxiang becam sharehold
convert joint-stock limit liabil compani renam
list neeq
toripalimab first monoclon antibodi develop prc compani receiv ind
one first humira biosimilar develop prc compani receiv ind
approv nmpa
complet merger absorpt shanghai union biopharm previous list neeq
first anti-bl monoclon antibodi develop prc compani receiv ind
admit innov layer compani list neeq
commenc construct lingang product base new manufactur base
first monoclon antibodi develop prc compani receiv ind
approv prc
obtain fda approv conduct clinic trial unit state toripalimab
start phase clinic trial unit state toripalimab
nda file toripalimab accept nmpa
charl martineau pm univers toronto figur sharehold corpor structur follow complet global offer
compani data assum over-allot option exercis without regard convert bond pre-ipo option
charl martineau pm univers toronto board manag
execut director chairman
execut director chief execut
offic gener manag
execut director chief oper
mr zhang zhuob execut director deputi gener
manag chief scienc offic
manag senior vice presid
chairman board director shanghai union biopharm
director sichuan huapu modern agricultur co ltd
chairman board director shanghai baoy
leader offic biostatist team leader mathemat statistician
statist review fda
vice presid asia regulatori affair global regulatori affair sanofi
guest professor clinic research institut peke univers
part-tim professor medic informat centr peke univers
scientist medimmun inc
product manag humanzym inc
director deputi gener manag shanghai union biopharm
legal repres execut director gener manag suzhou union biopharm
director beij xinjingk
senior scientist
scientist trelli bioscienc
postdoctor re affili stanford univers
director amplimmun inc subsidiari astrazeneca
associ research scientist human translat immunolog depart yale
research fellow john hopkin univers school medicin
chairman board director shenzhen finevalu capit co ltd
chairman board director shenzhen dingyuan growth invest manag
chairman board director jiangsu xinyun capit manag co ltd
region manag sale director gener manag tonghua dongbao
hillhous capit group
execut director shanghai shengg invest manag co ltd
gener manag china asset manag co ltd
founder chairman loyal valley innov capit
risk pertain drug approv
major risk pharmaceut compani focus drug approv approv
success rate drug alreadi enter phase clinic trial studi clinic
test expens take mani year complet outcom inher
uncertain failur occur time clinic trial process result
preclin studi earli clinic trial compani drug candid may
predict result later-stag clinic trial initi interim result trial
may predict final result failur drug approv could thu substanti
harm compani busi
risk delay drug approv
time requir drug approv us eu china regul may
unpredict compani current launch product thu delay
approv substanti harm busi chang regulatori requir
guidanc may also occur junshi may need amend clinic trial protocol submit
applic regulatori author reflect chang amend may requir
compani resubmit clinic trial protocol irb ethic committe re-
examin may impact cost time success complet clinic trial
develop commercialis new drug highli competit
compani commerci opportun could reduc elimin competitor develop
commercialis drug safer effect fewer less sever side
effect conveni less expens drug junshi develop
risk biolog manufactur
manufactur manufactur facil requir compli extens nmpa
fda compar regulatori author requir includ ensur qualiti
control manufactur procedur conform gmp applic regul
compani subject continu review inspect access complianc
gmp adher commit made nda bla behaviour
compli standard could caus seriou damag compani credit
product may suspend product
prc market gone signific reform pharmaceut industri
recent year may subject reform measur govern initi
oncolog drug price negoti group purchas lower drug price
compens pharmaceut manufactur insur coverag larger-
than-expect price cut drug impact compani revenu long-term
limit oper histori compani make difficult evalu busi
futur term busi continu financi perform junshi gener
revenu signific cost expect futur particular research
develop commercialis drug candid requir continu extern
financi support busi stake fail obtain suffici capit
resourc compani debt financ could result increas fix payment
oblig put financi pressur junshi transit biotech
pharma compani demonstr abil manufactur drug
commerci scale market sale capabl yet test
sinc compani grow fast pace manag team make mani
critic decis regard product develop financi strategi partnership
expans signific chang manag team may impact fundament
strategi junshi compani seek addit capit manag share
dilut may reduc control power ownership manag team
jurisdict reput risk
junshi may abl obtain maintain ip right protect technolog
product competitor may also abl circumv patent ip right
may protect throughout world patient get expect
clinic benefit may place charg compani could potenti damag
reput market
compani mention price
